Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26381747 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL888204 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL997382 | 1.00 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL15890590 | 0.98 | TSHR (0.46) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL19999151 | 0.91 | CYP2C19 (0.46) | MEN1KMT2ATSHRCYP2C19POLB | |
| SCHEMBL17883360 | 0.91 | CYP2C19 (0.46) | MEN1KMT2ATSHRCYP2C19POLB | |
| SCHEMBL1777653 | 0.89 | CYP2C19 (0.48) | TSHRCYP2C19POLBBLMATM | |
| SCHEMBL1469721 | 0.84 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL29518865 | 0.84 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1CYP2C19 | |
| SCHEMBL30372269 | 0.84 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095467-A1 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160195540-A1 | Molecular Conjugate | VENTANA MED SYST INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160195540-A1 | Molecular Conjugate | VENTANA MED SYST INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-9310373-B2 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9310373-B2 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2963011-A1 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-1951316-B1 | Molecular conjugate | VENTANA MED SYST INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140205995-A1 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205995-A1 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20100136652-A1 | Molecular Conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100136652-A1 | Molecular Conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2010-06-03 | — | — | US | disclosed |
| WO-2007062177-A2 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195540-A1 | Molecular Conjugate | CA12, FCGR2A, CA14 | MEN1 3359/4885KMT2A 181/4885TSHR 2108/4885 |
| US-20100136652-A1 | Molecular Conjugate | CA12, FCGR2A, CA14 | MEN1 3359/4885KMT2A 181/4885TSHR 2108/4885 |
| US-20070117153-A1 | Molecular conjugate | CA12, FCGR2A, CA14 | MEN1 3359/4885KMT2A 181/4885TSHR 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.